Overview

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The study is designed to compare the pharmacokinetics of generic tacrolimus (Sandoz) to branded tacrolimus (Prograf) in stable renal transplant patients.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
Sandoz
Treatments:
Tacrolimus